Newswise — Testing self-collected saliva samples could offer an easy and effective mass testing approach for detecting asymptomatic COVID-19. Scientists at Hokkaido University and colleagues in Japan have demonstrated a quick and effective mass testing approach using saliva samples to detect individuals who have been infected with COVID-19 but are still not showing symptoms. Their findings were published in the journal Clinical Infectious Diseases. "Rapid detection of asymptomatic infected individuals will be critical for preventing COVID-19 outbreaks within communities and hospitals," says Hokkaido University researcher Takanori Teshima, who led the study. Many of the world's governments are showing reluctance to re-institute full national lockdowns as second waves of COVID-19 infections loom on the horizon. Testing and tracing systems will need to be ramped up in order to detect and isolate people who have the virus as early as possible. Teshima and colleagues tested and compared the nasopharyngeal swabs and saliva samples of almost 2,000 people in Japan who did not have COVID-19 symptoms. Two different virus amplification tests were performed on most of the samples: the PCR test, which is now well-known and widely available around the world, and the less commonly used but faster and more portable RT-LAMP test. The number of positive and negative results in all samples was very similar, with the nasopharyngeal swabs and saliva samples able to detect those with the infection in 77-93% and 83-97% of subjects, respectively. Both two tests were also able to identify those without the infection in greater than 99.9% of subjects. The virus loads detected in nasopharyngeal swab and saliva were equivalent and highly correlated. Teshima says, "PCR sensitivity is much higher than previously thought 70% that came from initial data of symptomatic patients." While finding both nasopharyngeal and saliva samples have high sensitivity and specificity to the SARS-CoV-2, Teshima says "Saliva testing has significant logistic advantages over the commonly used nasopharyngeal swab testing." "Self-collection of saliva is painless for examinees, and more importantly, it eliminates the close contact with the examiners, reducing the risk of viral exposure." "We also found that it is unlikely that the sensitivity of RT-LAMP is significantly less than that of the PCR test, suggesting that it might be a useful alternative for diagnosing COVID-19 infection, especially where diagnosis is required at the point of sample collection, like in sports venues or at airports," says Teshima. Researchers point to a limitation of the study that they did not follow up with clinical outcomes. Nonetheless, they suggest that the results give good indication that mass screening using self-collected saliva and rapid RT-LAMP testing could provide easy, non-invasive, quick and relatively accurate results, with minimal risk of viral transmission to healthcare workers. Image Credit: Isao Yokota et al., Clinical Infectious Diseases, September 25, 2020 Both nasopharyngeal swab (NPS) and saliva testing showed high sensitivity and specificity to the SARS-CoV-2. (Isao Yokota et al., Clinical Infectious Diseases, September 25, 2020)
Newswise — From Weight Watchers to wearable tech – wherever we look, there are messages encouraging us to stay fit and healthy. But diets and training methods aside, when it comes to heart health, research from the University of South Australia shows that a far more personalised approach is needed…and it all starts with your genes. Conducted in partnership with the University of New England and the University of Queensland, the study assessed the impact of lifestyle factors on cardiovascular disease (CVD), finding clear links between genetic predisposition of CVD and smoking, alcohol intake, physical activity and diet. UniSA researcher, Associate Professor Hong Lee, leader of the statistical genetics group at the Australian Centre for Precision Health, says the popular ‘one-size-fits-all’ approach to heart health does not have uniform effects, and that a tailored, individualised approach to CVD is essential. Globally, CVD is the number one cause of death, claiming an estimated 17.9 million lives a year. Most deaths are due to heart attacks and strokes, with a third of these occurring prematurely in people under 70 years of age. In Australia, heart disease kills one Australian every four minutes. “Every day, we’re exposed to information that promotes positive lifestyle factors for better health. But what we don’t hear, is how individual genetic differences can negate positive effects, often to detriment of the individual,” Assoc Prof Lee says. “Between 20 to 60 per cent of risk factors for CVD are attributed to genetics which are far better addressed through personalised and individual interventions than broad-stroke lifestyle adjustments. “For example, genetics show how the level of your cholesterol can be controlled by a lifestyle modification, given your genotypes and the underlying genetic link between cholesterol and lifestyle factors. “This will help you make a decision about which lifestyle intervention is most suitable for you, for example, more exercise might be a better choice than reducing smoking. “However, this does not necessary mean that exercise is uniformly recommended for other people who may have different genes and genetic effects that are more sensitive to smoking exposure. “It’s all about understanding how individual genetic risks can change in line with different lifestyle adjustments, and consequently how cardiovascular health can benefit.” Using a novel whole-genome approach, researchers analysed 23 cardiovascular health-related traits and 22 lifestyle characteristics using the ARIC (Atherosclerosis Risk in Communities) Study (N=8291) and validating results via the UK Biobank (N~500,000). 34 significant CVD trait-lifestyle pairs were identified. While Assoc Prof Lee agrees that positive lifestyle changes are good for overall health, including cardiovascular health, he says tailored interventions based on individual differences will be most successful for managing CVD. “As precision health practices advance, we are likely to see more personalised health treatments that are based on individual genetic profiles,” Assoc Prof Lee says. “We are currently in the process of developing tools that can predict genetic risk based on genotypes and how lifestyle changes can modulate these. “Incorporating individual (genetic) differences into CVD interventions will absolutely increase the predictive power of lifestyle changes on individual health.”
SAN MARCOS, TX – R-Water announces Gary Rizzato has joined the company as Chief Operating Officer (COO). In his new role, Gary will draw from experiences within the healthcare industry where he managed expansion and build out projects surpassing $1 billion and oversaw facilities totaling more than 2.5 million square feet. He will closely collaborate with CEO Rayne Guest to ensure the company's rapid growth stays aligned with the founding values and culture. “I’ve been impressed with Gary since we met in 2015,” said Rayne Guest, founder and CEO of R-Water. “Gary’s commitment to quality care, operational efficiency, and customer service make him a perfect fit for our team.” Gary Rizzato has over a decade of experience working in healthcare facility management and support services. Most recently, he served as Vice President for the Government Division of HHS, a company serving more than 600 partner organizations in the fields of healthcare, resorts, senior living, government, aviation, and education. Gary also assisted in starting up and managing the HHS Integrated Facilities Management service line, serving in the role of Vice President of Integrated Facilities Management. Gary began his career working for healthcare systems, such as Tenet Health, Baton Rouge General Medical Center, and CHI St. Joseph Health. His various roles included Director of Facility Management, Property Manager, and Project Manager. “I am proud to join R-Water, said Gary Rizzato. “The mission of the company is one I whole-heartedly believe in and look forward to using my expertise to spread the positive impact it is making in the cleaning industry even further.” Gary received his bachelor’s degree in Environmental Design from Texas A&M University and his Master of Science in Engineering Science from Louisiana State University. He is a national design member with the American Institute of Architects (AIA), Certified Healthcare Facilities Manager (CHFM), Certified Healthcare Fire Safety Professional (CHFSP), Certified Healthcare Safety Professional (CHSP), Registered Environmental Services Executive (RESE), and possesses health and safety certifications OSHA 30 and EM 385-1-1. About R-Water R-Water is a woman-owned business based in San Marcos, Texas. R-Water’s computerized device gives hospitals, hotels, cruise ships, office buildings, restaurants, schools, and other facilities the power to produce cutting-edge cleaning and disinfecting solutions on-site. To learn more about how you can protect yourself against the threat of COVID-19, visit www.r-water.com or contact email@example.com.
Newswise — In a paper published in the Journal on Active Aging, University of Illinois Chicago longevity researcher S. Jay Olshansky and his colleagues conclude that both 2020 presidential candidates — former Vice President Joe Biden, 77, and President Donald Trump, 74 — are likely to maintain their health beyond the end of the next presidential term. As a result, they say that chronological age and fitness should not be factors in the 2020 election. “It is our conclusion that chronological age is not a relevant factor for either candidate running for President of the United States,” the authors write. “Both candidates face a lower than average risk of experiencing significant health or cognitive functioning challenges during the next four years.” To evaluate each candidate’s likelihood of surviving a four-year term in office, the researchers scientifically evaluated the candidates’ health status based on publicly available medical records and confirmed publicly available personal information. The medical records of each candidate were independently evaluated by three medical doctors with experience in aging and a team of research scientists with expertise in epidemiology, public health, survival analysis, and statistics. This is the first time that the medical records and personal attributes of presidential candidates have been scientifically evaluated by physicians and scientists in the field of aging. The key findings of the study: Biden and Trump are likely to be “super-agers,” a subgroup of people that maintain their mental and physical functioning and tend to live longer than the average person their age. Both candidates have a higher than average probability of surviving a four-year term in office, relative to other men their age. For Biden, the probability of surviving the next four years is 95.2% (vs. 82.2%). For Trump, this is 90.3% (vs. 86.2%). Biden is expected to outlive Trump, even though he is three years older. In the paper, the researchers note Biden’s “nearly perfect health profile for a man his age,” compared with Trump’s “significant but modifiable” risk factors. While Trump is noted to have an elevated familial risk of late-onset Alzheimer’s disease, neither candidate is expected to have major cognitive functioning challenges now or during the next four years. Olshansky, the corresponding author of the study, says the results are evidence that age does not matter in this historic election in which the next elected president will be the oldest in American history. “We see chronological age as a topic of discussion time and again during elections, even though scientific and medical evidence tells us that biological age is far more important,” said Olshansky, professor of epidemiology and biostatics at the UIC School of Public Health. Biological age is reflective of how rapidly a body is growing old — this occurs at different rates, Olshansky said. “Biological age is influenced by genetics and behavioral risk factors. Some people can be biologically old at age 50 while others can be biologically young at age 80.” In prior research, Olshansky conducted the first scientific evaluation of presidential longevity; he sought to understand if being President causes an individual to age more rapidly and die sooner than expected. In that study, Olshansky concluded that most U.S. presidents actually live beyond the average life expectancy. The new study is the first to evaluate individuals, before they are elected. “Despite the science, the candidates themselves and their campaigns are still trying to weaponize age,” Olshansky said. “This is certainly the case for both campaigns in 2020. Comments from Biden implying that Trump is ‘mentally deranged’ and Trump’s references to Biden as ‘Sleepy Joe’ suggest that their opponents are too old, are unfit, or are otherwise unable to do the job, based on their age. It’s ageism, pure and simple.” Tolerance of ageism, Olshansky says, harms everyone. “We live in an aging society, and it’s important that we value, respect and continue to have a place in our culture for people of all ages. No one should be discounted from any position, even the presidency, based on their age,” Olshansky said. Olshansky thinks that the public would be better served if age was diffused as a factor in elections rather than weaponized, and he’s seen other candidates refuse to contribute to an ageist narrative. “Ronald Regan did this in the 80s and Pete Buttigieg did it last year. Age should not be a topic in 2020,” Olshansky said. In 1984, Ronald Regan, then age 73, when asked about his advanced age, said “I want you to know that also I will not make age an issue of this campaign. I am not going to exploit, for political purposes, my opponent’s youth and inexperience.” Similarly, when asked about his relative youth, Sound Bend, Indiana Mayor Pete Buttigieg, who ran in the 2019 democratic presidential primary, then age 37, deflected the question. “Mayor Buttigieg said it’s the age of the ideas that matter, not the candidate — and I think that was right, too,” Olshansky said. “We can acknowledge age in an election, but all ages should be valued for the diverse perspectives and experience they bring.” Co-authors on the paper are Hiram Beltrán-Sánchez of the University of California, Los Angeles; Yang Claire Yang of the University of North Carolina at Chapel Hill; Yi Li of the University of Macao; Dr. Nir Barzilai of the Albert Einstein College of Medicine; Dr. Paola Rode of Lapetus Solutions; and Dr. Bradley Willcox of the University of Hawaii.
Newswise — Middle-aged adults who report symptoms of insomnia and are sleeping less than six hours a night may be at increased risk of cognitive impairment, according to a study by Penn State College of Medicine researchers. The results may help health care professionals understand which patients who report insomnia are at increased risk for developing dementia. Insomnia is characterized by reports of difficulty falling asleep, difficulty staying asleep or waking up too early and not being able to get back to sleep. When these symptoms occur at least 3 nights a week and for at least 3 months, it is considered a chronic disorder. Researchers found that adults who reported insomnia and obtained less than six hours of measured sleep in the laboratory were two times more likely to have cognitive impairment than people with the same insomnia complaints who got six or more hours of sleep in the lab. The study results were published in the journal SLEEP on September 24. According to Julio Fernandez-Mendoza, associate professor of psychiatry and behavioral health and sleep specialist at Penn State Health Sleep Research and Treatment Center, about 25% of the adult general population reports insomnia symptoms and another 10% suffers from chronic insomnia. He said that being able to distinguish which of these individuals are at risk for further adverse health conditions is critical. “This study reinforces the need to objectively measure the sleep of adults who complain of insomnia,” Fernandez-Mendoza said. In previous research, the team found that adults with insomnia who obtained less than six hours of sleep were at risk for various cardiometabolic conditions, including hypertension, diabetes, heart disease or stroke and mental health problems, such as depression. “These new results demonstrate that these middle-aged adults also have an increased risk of cognitive impairment, which can be an early indicator of future dementia in a significant proportion of them,” Fernandez-Mendoza said. Researchers examined data from the Penn State Adult Cohort, a randomly-selected, population-based sample of 1,741 adults who had one measured night of sleep. Before having their sleep measured in a sound, light and temperature-controlled room, participants completed a clinical history, physical exam and questionnaire to identify self-reported sleep disorders, physical health conditions, mental health problems and substance use. They also were evaluated for cognitive impairment before sleeping in the laboratory including tests that assessed attention, memory, language and other measures. Fernandez-Mendoza and colleagues found that adults who reported insomnia symptoms or chronic insomnia and slept less than six hours in the lab were two times more likely to have cognitive impairment when compared to good sleepers. They also found that this association was particularly strong for adults with coexisting cardiometabolic conditions and cognitive impairment, which may be an indicator of vascular cognitive impairment – a condition where poor cardiovascular health results in impaired brain function. Adults who reported insomnia but who slept six or more hours in the lab were not at risk of cognitive impartment when compared to good sleepers. The research team accounted for potential differences in sociodemographic factors – including age, sex, race, ethnicity, years of education – and the presence of physical and mental health problems, including sleep apnea, as well as substance use, such as smoking and alcohol intake. Fernandez-Mendoza said that only having one measured night of sleep limited the study’s conclusion to in-lab sleep studies and cautioned that these data do not prove causality. Nevertheless, they further show that insomnia, cognitive impairment and cardiometabolic conditions, like high blood pressure, diabetes and heart disease, often tend to co-occur in adults who get less than six hours of sleep in the lab but not in those who can sleep six hours or more, he highlighted. “This study is important because it is the first large U.S. prospective study associating insomnia with cognitive risk,” said Michael Twery, director of the National Center on Sleep Disorders Research of the National Heart, Lung, and Blood Institute, part of the National Institutes of Health and one of the study’s funders. “Recent scientific advances indicate that the brain depends on sleep. Understanding the connection between sleep deficiency and early cognitive decline could lead to improved treatments for insomnia.” Fan He, Kristina Puzino, Gregory Amatrudo, Susan Calhoun, Duanping Liao, Alexandros Vgontzas and Edward Bixler of Penn State College of Medicine also contributed to this research. The researchers declared no conflict of interest. This research is supported in part by the American Heart Association (AHA) under award number 14SDG19830018 and the National Institutes of Health (NIH) under award numbers R01HL51931 and R01HL40916. The content is solely the responsibility of the authors and does not necessarily represent the official views of AHA or NIH. About Penn State College of MedicineLocated on the campus of Penn State Health Milton S. Hershey Medical Center in Hershey, Pa., Penn State College of Medicine boasts a portfolio of nearly $100 million in funded research. Projects range from development of artificial organs and advanced diagnostics to groundbreaking cancer treatments and understanding the fundamental causes of disease. Enrolling its first students in 1967, the College of Medicine has more than 1,700 students and trainees in medicine, nursing, other health professions and biomedical research in both Hershey and State College, Pa.
Newswise — MINNEAPOLIS – Supplements that claim to improve mental focus and memory may contain unapproved pharmaceutical drugs and in potentially dangerous combinations and doses, according to a new study published in the September 23, 2020, online issue of Neurology® Clinical Practice, an official journal of the American Academy of Neurology. Researchers found five such drugs not approved in the United States in the supplements they examined. The supplements are sometimes called “nootropics,” “smart drugs” or “cognitive enhancers.” “Over-the-counter cognitive supplements are popular because they promise a sharper mind, but they are not as closely regulated as pharmaceutical drugs,” said study author Pieter A. Cohen, M.D., of Harvard Medical School in Boston, Mass. “Use of these supplements poses potentially serious health risks. Not only did we detect five unapproved drugs in these products, we also detected several drugs that were not mentioned on the labels, and we found doses of unapproved drugs that were as much as four times higher than what would be considered a typical dose.” Cohen said the supplements could be especially risky if used in combination with prescriptions drugs or instead of seeking medical advice. Unlike pharmaceutical drugs that must be proven safe and effective for their intended use before they are marketed to consumers, the law does not require the U.S. Food and Drug Administration (FDA) to approve dietary supplements for safety or effectiveness before they reach the consumer. The FDA takes action after the products reach the market if they are mislabeled or contain unapproved products. For the study, researchers searched the National Institutes of Health Dietary Supplement Label Database and the Natural Medicines Database for cognitive supplements that listed drugs similar to piracetam, a drug previously found in supplements but not approved in the U.S. They were looking for analogs of piracetam, drugs with a similar but slightly different chemical structure. Analogs are sometimes introduced into supplements to circumvent laws. Researchers identified 10 supplements, eight that promised to enhance mental function, one that was marketed as “workout explosives” and another that had the words “outlast, endure, overcome” on the label. Researchers examined the contents of each supplement using various methods and measured quantities of each drug present. In the 10 supplements they examined, researchers detected five unapproved drugs. Two were analogs of piracetam called omberacetam and aniracetam. The others were the unapproved drugs vinpocetine, phenibut and picamilon. The FDA has issued a warning that vinpocetine should not be consumed by women of childbearing age. While all of the risks of these drugs are not known, side effects include increased and decreased blood pressure, agitation, sedation and hospitalization. All 10 supplements contained omberacetam, which is prescribed in Russia for traumatic brain injury and mood disorders. A typical pharmaceutical dose would be 10 milligrams (mg). The doses in a recommended supplement serving size were as high as 40 mg, four times greater than in pharmaceutical dosages. Some supplements contained more than one unapproved drug. One product combined four of the unapproved drugs. “With as many as four unapproved drugs in individual products, and in combinations never tested in humans, people who use these cognitive enhancement supplements could be exposing themselves to potentially serious health risks,” said Cohen. “The effects of consuming untested combinations of unapproved drugs at unpredictable dosages are simply unknown and people taking these supplements should be warned.” Researchers also found that for those products with drug quantities provided on the labels, a majority of the declared quantities were inaccurate. “The fact that these supplements are listed in official databases does not mean the labeling is accurate or the dosage levels of ingredients in these supplements are safe,” said Cohen. “U.S. law does not permit unapproved pharmaceuticals to be introduced into dietary supplements, but the law places the burden of eliminating those products on the FDA. The FDA has issued a series of warnings to companies selling supplements with unapproved drugs, yet such drugs remain openly listed on databases as ingredients in supplements. Our study also raises concerns regarding the quality and legality of supplements listed in supplement databases.” One limitation of the study was that it didn’t look at all unapproved drugs that are marketed in cognitive supplements. Learn more about brain health at BrainandLife.org, home of the American Academy of Neurology’s free patient and caregiver magazine focused on the intersection of neurologic disease and brain health. Follow Brain & Life® on Facebook, Twitter and Instagram. When posting to social media channels about this research, we encourage you to use the hashtags #Neurology and #AANscience. The American Academy of Neurology is the world’s largest association of neurologists and neuroscience professionals, with over 36,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer’s disease, stroke, migraine, multiple sclerosis, concussion, Parkinson’s disease and epilepsy. For more information about the American Academy of Neurology, visit AAN.com or find us on Facebook, Twitter, Instagram, LinkedIn and YouTube.
Newswise — Scientists at Sanford Burnham Prebys Medical Discovery Institute, Fondazione Santa Lucia IRCCS, and Università Cattolica del Sacro Cuore in Rome have shown that pharmacological (drug) correction of the content of extracellular vesicles released within dystrophic muscles can restore their ability to regenerate muscle and prevent muscle scarring (fibrosis). The study, published in EMBO Reports, reveals a promising new therapeutic approach for Duchenne muscular dystrophy (DMD), an incurable muscle-wasting condition, and has far-reaching implications for the field of regenerative medicine. “Our study shows that extracellular vesicles are bioactive mediators that can transfer the benefits of medicine—in this case, HDAC inhibitors (HDACi)—to treat DMD,” says Pier Lorenzo Puri, M.D., professor in the Development, Aging and Regeneration Program at Sanford Burnham Prebys and co-corresponding author of the study. “We discovered the promise of this treatment almost 20 years ago and did all of the preclinical work, which led to a current clinical trial for boys with DMD. However, the therapeutic potential of HDACi has been so far limited by its systemic adverse effects.” In the current clinical trial, boys with DMD are treated with HDACi at suboptimal doses due to the risk of adverse side effects. The scientists are hopeful that extracellular vesicles might provide a cell-free, non-immunogenic, transplantable tool for local delivery of bioactive particles that transfer HDACi to dystrophic muscles, thereby overcoming the undesirable secondary effects caused by chronic use at high doses. “We believe this novel approach of using pharmacologically corrected extracellular vesicles may be used to safely deliver drugs such as HDACi directly to dystrophic muscles to obtain the beneficial action that would otherwise only be achieved at higher, toxic doses,” says Puri. Extracellular vesicles are bioactive particles, meaning they have an effect in the body. They have recently attracted significant attention from the biomedical community because of their therapeutic potential. These particles contain information in the form of DNA, RNA or proteins and are exchanged from one cell to another. Alterations in the content of these particles leads to faulty communication between cells in dystrophic muscles and changes their behavior. In this study, the scientists discovered that these content alterations can be corrected to restore the physiological communication between the cells of dystrophic muscles. Communication breakdown Prior research from Puri’s team showed that as DMD progresses, special muscle-healing cells called fibro-adipogenic progenitors (FAPs) become corrupted and start to promote muscle wasting and fibrosis. The team suspected that altered communication between FAPs and muscle stem cells—perhaps via extracellular vesicles—might be part of the problem. To answer this question, Martina Sandonà, Ph.D., first author of the study, and her colleagues conducted a series of experiments using muscle biopsies from boys with DMD who are enrolled in the clinical trial testing experimental HDACi treatment as well as a mouse model of DMD. The scientists were able to show that as DMD progresses, cellular communication via extracellular vesicles is progressively altered over time, which impairs the regeneration potential of DMD muscles. Importantly, the researchers demonstrated that correcting the content of the extracellular vesicles with an HDAC inhibitor activates muscle stem cells and promotes regeneration while reducing fibrosis and inflammation. “Our findings can likely be extended to other conditions and diseases, as pharmacologically ‘lifted’ extracellular vesicles could be exploited as a general therapeutic tool in regenerative medicine,” says Valentina Saccone, Ph.D., group leader at Fondazione Santa Lucia IRCCS, tenured assistant professor at Università Cattolica del Sacro Cuore and co-corresponding author of the study. “These particles might also be used as an adjuvant approach for other treatments, such as gene or cell therapies.” A ray of hope Treatment advances can’t come soon enough for people with DMD and their loved ones. The genetic condition is caused by a lack of dystrophin, a protein that strengthens muscles, and causes progressive muscle degeneration. DMD primarily affects boys, with symptoms often appearing between the ages of 3 and 5. With recent medical advances, children with DMD now often survive beyond their teenage years into their early 30s, but effective treatments are still needed. “For children and adults living with DMD and their families, research provides a ray of hope for a better future,” says Filippo Buccella, founder of Parent Project Italy, which has provided continual support to Puri’s team for the last 20 years. “This study uncovers a promising new therapeutic approach for DMD and brings us one step closer to treatments that may help children maintain muscle strength for as long as possible and live long, fulfilling lives.” “The more options we have to treat DMD, the better, as it’s likely that drugs with different mechanisms of action could be more effective in combination,” says Sharon Hesterlee, Ph.D., executive vice president and chief research officer of the Muscular Dystrophy Association. “Dr. Puri’s work represents a unique approach that could prove complementary.” A global team The co-first authors of the study are Martina Sandonà of Fondazione Santa Lucia and Sapienza University of Rome; and Silvia Consalvi of Fondazione Santa Lucia. Additional study authors include Luca Tucciarone of Fondazione Santa Lucia and Sapienza University of Rome; Marco De Bardi and Daniela Francesca Angelini of Fondazione Santa Lucia; Manuel Scimeca of the University of Rome “Tor Vergata”; Valentina Buffa and Antonella Bongiovanni of the National Research Council of Italy; Adele D’Amico and Enrico Silvio Bertini of the Bambino Gesù Children’s Hospital; Sara Cazzaniga of Paolo Bettica of Cinisello Balsamo; and Marina Bouché of Sapienza University of Rome. This work is supported by the National Institutes of Health (1R01AR076247-01, R01GM134712-01), Duchenne Parent Project Italy and Netherland, the Muscular Dystrophy Association, Epigen, Association Française contre les Myopathies, and the Italian Ministry of Health (GR2016-02362451). The study’s DOI is 10.15252/embr.202050863. Photo Credit/Caption: Sanford Burnham Prebys Medical Discovery Institute As Duchenne muscular dystrophy progresses, levels of a beneficial RNA (purple), called miR-206, in muscles decrease over time. In the study, the scientists were able to boost the amount of miR-206 in extracellular vesicles that are delivered to muscle stem cells, which promoted muscle repair.
Antibodies may not be body's primary defense against coronaviruses; T-cells can last decades Newswise — More than 100 companies have rushed into vaccine development against COVID-19 as the U.S. government pushes for a vaccine rollout at "warp speed" -- possibly by the end of the year -- but the bar set for an effective, long-lasting vaccine is far too low and may prove dangerous, according to Marc Hellerstein of the University of California, Berkeley. Most vaccine developers are shooting for a robust antibody response to neutralize the virus and are focusing on a single protein, called the spike protein, as the immunizing antigen. Yet, compelling evidence shows that both of these approaches are problematic, said Hellerstein, a UC Berkeley professor of nutritional sciences and toxicology. A better strategy is to take a lesson from one of the world's best vaccines, the 82-year-old yellow fever vaccine, which stimulates a long-lasting, protective T-cell response. T-cells are immune cells that surveil the body continuously for decades, ready to react quickly if the yellow fever virus is detected again. "We know what really good vaccines look like for viral infections," Hellerstein said. "While we are doing phase 2 trials, we need to look at the detailed response of T-cells, not just antibodies, and correlate these responses with who does well or not over the next several months. Then, I think, we will have a good sense of the laboratory features of vaccines that work. If we do that, we should be able to pick good ones." Using a technique Hellerstein's laboratory developed and perfected over the past 20 years that assesses the lifespan of T-cells, it is now possible to tell within three or four months whether a specific vaccine will provide long-lasting cells and durable T-cell-mediated protection. Hellerstein laid out his arguments in a review article published today in the journal Vaccine. "There isn't a lot of room for major error here," Hellerstein said. "We can't just go headfirst down a less than optimal or even dangerous avenue. The last thing we want is for immunized people to get sick in a few months or a year, or get sicker than they would have. Whoever is paying for or approving the vaccine trials has the obligation to make sure that we look at the quality and durability of the T-cell response. And this would not delay the licensing process." Misplaced focus on antibodies Hellerstein points out that antibodies are not the primary protective response to infection by coronaviruses, the family of viruses that includes SARS-CoV-2. Indeed, high antibody levels to these viruses are associated with worse disease symptoms, and antibodies to coronaviruses, including SARS-CoV-2, don't appear to last very long. This was noted in people infected by the first SARS virus, SARS-CoV-1, in 2003. SARS patients who subsequently died had higher antibody levels during acute infection and worse clinical lung injury compared to SARS patients who went on to recover. In MERS, which is also a coronavirus infection, survivors with higher antibody levels experienced longer intensive care unit stays and required more ventilator support, compared to subjects with no detectable antibodies. In contrast, strong T-cell levels in SARS and MERS patients correlated with better outcomes. The same has also played out, so far, in COVID-19 patients. "A strong antibody response correlates with more severe clinical disease in COVID-19, while a strong T-cell response is correlated with less severe disease. And antibodies have been short-lived, compared to virus-reactive T-cells in recovered SARS patients," Hellerstein said. The most worrisome part, he said, is that antibodies also can make subsequent infections worse, creating so-called antibody-dependent enhancement. Two vaccines -- one against a coronavirus in cats and another against dengue, a flavivirus that affects humans -- had to be withdrawn because the antibodies they induced caused potentially fatal reactions. If an antibody binds weakly against these viruses or falls to low levels, it can fail to "neutralize" the virus, but instead help it get into cells. Antibody-dependent enhancement is well known in diseases such as dengue and Zika. A recent UC Berkeley study in Nicaragua showed that antibodies produced after infection with Zika can cause severe disease, including deadly hemorrhagic fever, in those later infected by dengue, a related viral disease. This dangerous cross-reaction may also occur with antibodies produced by a vaccine. Hellerstein noted that a robust T-cell response is key to maintaining high levels of antibodies and may prevent or counteract antibody-dependent enhancement. T-cells are a long-lasting defense Hellerstein primarily studies the dynamics of metabolic systems, tagging the body's proteins and cells with a non-radioactive isotope of hydrogen, deuterium and tracking them through the living body. He began to study the birth and death rates of T-cells in HIV/AIDS patients over 20 years ago, using sophisticated mass spectrometric techniques designed by his laboratory. Then, three years ago, he teamed up with immunologist Rafi Ahmed and his colleagues at Emory University to determine how long T-cells induced by the yellow fever vaccine stick around in the blood. Surprisingly, he said, the same T-cells that were created to attack the yellow fever virus during the first few weeks after a live virus vaccination were still in the blood and reactive to the virus years later, revealing a remarkably long lifespan. He and the team estimated that the anti-yellow fever T-cells lasted at least 10 years and probably much longer, providing lasting protection from just one shot. Their long lifespan allows these cells to develop into a unique type of protective immune cell. "They (the T-cells) are a kind of adult stem cell, sitting silently in very small numbers for years or decades, but when they see viral antigen they go wild -- divide like crazy, put out cytokines and do other things that help to neutralize the virus," he said. "They are like seasoned old soldiers resting quietly in the field, ready to explode into action at the first sign of trouble." The same deuterium-labeling technique could be employed to measure the durability of a COVID-19 vaccine's T-cell response, helping to pinpoint the best vaccine candidates while trials are ongoing, he said. "We can, in my view, tell you the quality and durability or longevity of your T-cell response within a few months," he said. "These tests can be used to judge vaccines: Is a candidate vaccine reproducing the benchmarks that we see in highly effective vaccines, like the ones against smallpox and yellow fever?" Hellerstein said that he was motivated to write a review on the role of antibodies versus T-cells in protective immunity against SARS-Cov-2 when he heard from experts in vaccine development that companies would likely not be interested in testing anything beyond the antibody response. The reason given was that it would slow down the approval process or could even turn up problems with a vaccine. "That is why I wrote this review, honestly, because I was so upset by this response," he said. "At this moment in history, how can we not want to know anything that might help us? We need to get beyond the narrow focus on antibodies and look at the breadth and durability of T-cells." Worrisome focus on spike protein Hellerstein was also alarmed that most vaccines under development are focusing exclusively on inducing an antibody response against only one protein, or antigen, in the COVID-19 virus: the spike protein, which sits on the surface of the virus and unlocks the door into cells. But important new studies have shown that natural infection by SARS-CoV-2 stimulates a broad T-cell response against several viral proteins, not just against the spike protein. T-cells produced after natural infection in SARS patients are also very long-lived, he said. A recent study showed that patients who recovered from SARS-CoV-1 infection in 2003 produced CD4 and CD8 T-cells that are still present 17 years later. These T-cells also react to proteins in today's SARS-CoV-2, which the patients were never exposed to, indicating that T-cells are cross-reactive against different coronaviruses -- including coronaviruses that cause common colds. These findings all call into question whether limiting a vaccine to one protein, rather than the complement of viral proteins that the body is exposed to in natural infection, will induce the same broad and long-lasting T-cell protection that is seen after natural infection. In contrast, vaccines like the yellow fever vaccine that employ attenuated viruses -- viruses that divide, but are crippled and can't cause damage to the body -- tend to generate a robust, long-lasting and broad immune response. "If you are going to approve a vaccine based on a laboratory marker, the key issue is, 'What is its relationship to protective immunity?' My view is that T-cells have correlated much better than antibodies with protective immunity against coronaviruses, including this coronavirus. And T- cells haven't shown a parallel in COVID-19 to antibody-dependent enhancement that could make things worse, not better," he said. The effectiveness and durability of the first COVID-19 vaccines could impact, for years, the public's already questioning attitude toward vaccines, he warned. "It would be a public health and 'trust-in-medicine' nightmare, with potential repercussions for years -- including a boost to anti-vaccine forces -- if immune protection wears off or antibody-dependent enhancement develops and we face recurrent threats from COVID-19 among the immunized," he wrote in his review article.
A new computer model developed by Stanford researchers could help policymakers choose the right reopening strategy. Newswise — Pandemics bring pain. But so do the prescriptions for containing them: From school closures to total lockdowns, every government-mandated approach to blunting the impact of COVID-19 involves a trade-off between lives saved and jobs lost. Unfortunately, predicting the double-barreled economic and health effects of such policies has been difficult. Until now. Stanford Graduate School of Business economists Mohammad Akbarpour and Shoshana Vasserman, together with Cody Cook, a PhD candidate at Stanford GSB, and colleagues at several other universities (see sidebar), have developed a computer model that can for the first time estimate the combined health and wealth outcomes of different policy responses to the coronavirus pandemic. By computing the effects of different policies at different stages, the researchers were able to predict the impact of various reopening strategies on lives and livelihoods alike. From Congestion Pricing to COVID-19 Prior to the emergence of COVID-19, Akbarpour and Vasserman were mulling the use of cellphone location data to study congestion pricing. When the pandemic erupted, Akbarpour and Vasserman suspected that the same data, which allows researchers to create computer-based populations of virtual people who move about and interact like real ones, could be used to model its spread. They were right. Using a combination of cellphone and demographic data provided by the transportation-planning startup Replica, the team constructed virtual versions of New York City, Sacramento, and Chicago and mapped the contacts between individuals as they did such things as going to work, attending school, and shopping for groceries. By adding health, demographic, and occupational data drawn from electronic medical records and occupational surveys, the researchers were able to chunk the individuals in their virtual cities into hundreds of different types, such as 40-year-old men with diabetes who work in manufacturing, or 50-year-old women who work in technology and suffer from obesity, and so on. They then calculated all of the contacts that each type of individual would have with the others on an average day and fed that information into an epidemiological model. The model predicted how many people would be sickened, quarantined, and killed as the coronavirus spread. By imposing different policies (e.g., having everyone but essential workers stay home, requiring people to work remotely if possible), the researchers could alter the outcomes for each population. Because of the unique combination of health and occupational data they employed, they were able to estimate everything from the total number of hospitalizations and deaths to the total number of work days lost under each scenario. Chicago Is Not Sacramento In attempting to reopen their cities, officials have struggled to answer two basic questions: How do the health and economic outcomes of different reopening strategies compare? And do those outcomes vary from place to place? “We wanted a data-driven way to address that,” Vasserman says. There is a huge difference between what the same policy can do in Sacramento and what it can do in Chicago. Mohammad Akbarpour The model revealed that a so-called cautious reopening involving no formal restrictions on workplaces would lead to the greatest number of deaths but not to the lowest employment losses — presumably because even people who are totally free to work cannot do so if they are sick, quarantined, or dead. Requiring people to work from home when possible, however, would greatly reduce the number of deaths while only marginally increasing the number of work days lost. So would requiring students and workers to come into school or work on alternate shifts or days. But the impact of such policies varied widely from one city to another. “There is a huge difference between what the same policy can do in Sacramento and what it can do in Chicago,” says Akbarpour. For example, the model predicted that having people work remotely in Chicago would reduce deaths by 40 percent over a baseline return-to-normal scenario. But it would only reduce them by 20 percent in New York City, and hardly at all in Sacramento. Even the impact of personal voluntary practices like masking and social distancing differed from city to city. Overall, the model showed that masking was more effective at reducing deaths than any single government-mandated policy. But whereas masks only had to reduce infections by 10 percent to save more lives than a work-from-home policy in either New York City or Sacramento, they needed to reduce infections by at least 50 percent to achieve the same result in Chicago. The team traced these disparities to a host of factors, with everything from the total number of contacts among individuals to the timing of the pandemic itself (i.e., whether a city was hit hard early on or spared until later) affecting local outcomes. As a result, says Akbarpour, while the general recommendations remain largely the same, local prescriptions will vary. Next Steps The team is currently adding data on race and income to their model to explore the unequal impact that policies can have on different demographic groups. They also plan to compare the consequences of shutting down specific kinds of businesses (e.g., restaurants versus nail salons) and to evaluate the spillover effect of suppressing entire sectors of the economy (i.e., what happens to coffee shop baristas if office workers all work from home?). And they recently launched a website that allows users to compare the potential economic and health impacts of various policy mixes on a growing list of simulated cities. (They now have Replica data for Kansas City and are hoping to expand further.) “The hope is that policymakers will use this to explore what could happen,” Vasserman says. “But if they really want to make decisions, they should put in the time and resources to get something tailor-made to their situation.” https://www.gsb.stanford.edu/insights/mapping-good-bad-pandemic-related-restrictions Photo credit/caption: Reuters/Brian Snyder The research team mapped the contacts between individuals as they did such things as going to work, attending school, and shopping for groceries.
Findings support use of county-level cell phone location data as tool to estimate future trends of the COVID-19 pandemic Newswise — Cambridge, Mass. - In March 2020, federal officials declared the COVID-19 outbreak a national emergency. Around the same time, most states implemented stay-at-home advisories - to different degrees and at different times. Publicly available cell phone location data - anonymized at the county-level - showed marked reductions in cell phone activity at the workplace and at retail locations, as well as increased activity in residential areas. However, it was not known whether these data correlate with the spread of COVID-19 in a given region. In a new study published in JAMA Internal Medicine, researchers from Mount Auburn Hospital and the University of Pennsylvania analyzed anonymous, county-level cell phone location data, made publicly available via Google, and incidence of COVID-19 for more than 2,500 U.S. counties between January and May 2020. The researchers found that changes in cell phone activity in workplaces, transit stations, retail locations, and at places of residence were associated with COVID-19 incidence. The findings are among the first to demonstrate that cell phone location data can help public health officials better monitor adherence to stay-at-home advisories, as well as help identify areas at greatest risk for more rapid spread of COVID-19. "This study demonstrates that anonymized cell phone location can help researchers and public health officials better predict the future trends in the COVID-19 pandemic," said corresponding author Shiv T. Sehra, MD, Director of the Internal Medicine Residency Program at Mount Auburn Hospital. "To our knowledge, our study is among the first to evaluate the association of cell phone activity with the rate of growth in new cases of COVID-19, while considering regional confounding factors." Sehra and colleagues, including senior author Joshua F. Baker, MD, MSCE, of the University of Pennsylvania, incorporated publicly available cell phone location data and daily reported cases of COVID-19 per capita in majority of U.S. counties (made available by Johns Hopkins University), and adjusted the data for multiple county- and state- level characteristics including population density, obesity rates, state spending on health care, and many more. Next, the researchers looked at the change in cell phone use in six categories of places over time: workplace, retail locations, transit stations, grocery stores, parks and residences. The location data showed marked reductions in cell phone activity in public places with an increase in activity in residences even before stay-at-home advisories were rolled out. The data also showed an increase in workplace and retail location activity as time passed after stay-at-home advisories were implemented, suggesting waning adherence to the orders over time, information that may potentially be useful at a public health level. The study showed that urban counties with higher populations and a higher density of cases saw a larger relative decline in activity outside place of residence and a greater increase in residential activity. Higher activity at the workplace, in transit stations and retail locations was associated with a higher increase in COVID-19 cases 5, 10, and 15 days later. For example, at 15 days, counties with the highest percentage of reduction in retail location cell phone activity -- reflecting greater adherence to stay-at-home advisories -- demonstrated 45.5 percent lower rate of growth of new cases, compared to counties with a lesser decline in retail location activity. "Some of the factors affecting cell phone activity are quite intuitive," said Sehra, who is also an Assistant Professor of Medicine at Harvard Medical School. "But our analysis helps demonstrate the use of anonymous county-level cell phone location data as a way to better understand future trends of the pandemic. Also, we would like to stress that these results should not be used to predict the individual risk of disease at any of these locations."